Brief: Adma Biologics Sees FY Revenue $130 Million Or More

ADMA Biologics

11/05/2022 23:03

May 11 (Reuters) - ADMA Biologics Inc  ADMA.O :
    * SEES FY REVENUE $130 MILLION OR MORE 
    * ADMA BIOLOGICS ANNOUNCES FIRST QUARTER 2022 FINANCIAL
RESULTS
AND PROVIDES BUSINESS UPDATE
    * Q1 LOSS PER SHARE $0.13
    * Q1 REVENUE ROSE 81 PERCENT TO $29.1 MILLION
    * REITERATES EXPECTATIONS TO GROW REVENUES AND GROSS PROFITS
AND
NARROW NET LOSSES AS 2022 PROGRESSES
    * ADMA BIOLOGICS - BELIEVE ADMA IS ON TRACK TO POTENTIALLY
GENERATE $250 MILLION IN TOPLINE REVENUE IN 2024, AND $300
MILLION THEREAFTER

Further company coverage:  ADMA.O 

 ((Reuters.Briefs@thomsonreuters.com;))